Black Titan Corp (NASDAQ:BTTC – Get Free Report) fell 1% on Friday . The stock traded as low as $1.8007 and last traded at $1.89. 76,354 shares changed hands during trading, a decline of 98% from the average session volume of 3,903,502 shares. The stock had previously closed at $1.91.
Analysts Set New Price Targets
Separately, Weiss Ratings initiated coverage on Black Titan in a research report on Monday. They issued a “sell (e-)” rating for the company. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.
Get Our Latest Stock Analysis on BTTC
Black Titan Trading Down 1.0%
Black Titan Company Profile
Titan Pharmaceuticals, Inc is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.
Recommended Stories
- Five stocks we like better than Black Titan
- Do not delete, read immediately
- NEW LAW: Congress Approves Setup For Digital Dollar?
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- A U.S. “birthright” claim worth trillions – activated quietly
- The Crash Has Already Started (Most Just Don’t See It Yet)
Receive News & Ratings for Black Titan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Titan and related companies with MarketBeat.com's FREE daily email newsletter.
